share_log

UnitedHealth Group (NYSE:UNH) Price Target Raised to $617.00

Financial News Live ·  Jan 28, 2023 04:19

UnitedHealth Group (NYSE:UNH – Get Rating) had its price objective increased by Deutsche Bank Aktiengesellschaft from $615.00 to $617.00 in a report released on Tuesday, The Fly reports. They currently have a buy rating on the healthcare conglomerate's stock.

A number of other equities analysts have also recently issued reports on the stock. SVB Leerink dropped their price objective on shares of UnitedHealth Group from $625.00 to $618.00 and set an outperform rating for the company in a research note on Monday, October 17th. Loop Capital upped their target price on shares of UnitedHealth Group from $575.00 to $590.00 in a report on Tuesday, January 17th. Credit Suisse Group upped their target price on shares of UnitedHealth Group from $590.00 to $610.00 and gave the stock an outperform rating in a report on Wednesday, December 7th. Morgan Stanley reaffirmed an overweight rating and issued a $587.00 target price on shares of UnitedHealth Group in a report on Wednesday, November 23rd. Finally, Raymond James lowered shares of UnitedHealth Group from a strong-buy rating to an outperform rating and set a $615.00 target price on the stock. in a report on Monday, November 21st. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $599.39.

Get UnitedHealth Group alerts:

UnitedHealth Group Price Performance

NYSE:UNH opened at $486.05 on Tuesday. The stock has a market cap of $454.14 billion, a P/E ratio of 22.94, a PEG ratio of 1.38 and a beta of 0.73. UnitedHealth Group has a one year low of $445.73 and a one year high of $558.10. The company has a fifty day moving average price of $517.61 and a 200 day moving average price of $523.64. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.77 and a quick ratio of 0.82.

UnitedHealth Group (NYSE:UNH – Get Rating) last released its earnings results on Friday, January 13th. The healthcare conglomerate reported $5.34 EPS for the quarter, beating the consensus estimate of $5.17 by $0.17. UnitedHealth Group had a net margin of 6.21% and a return on equity of 27.04%. The firm had revenue of $82.79 billion during the quarter, compared to analysts' expectations of $82.53 billion. During the same period in the prior year, the company earned $4.48 EPS. The business's quarterly revenue was up 12.3% compared to the same quarter last year. Analysts anticipate that UnitedHealth Group will post 24.91 earnings per share for the current year.

UnitedHealth Group Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 13th. Stockholders of record on Monday, December 5th were paid a $1.65 dividend. This represents a $6.60 annualized dividend and a dividend yield of 1.36%. The ex-dividend date of this dividend was Friday, December 2nd. UnitedHealth Group's dividend payout ratio (DPR) is presently 31.15%.

Insider Activity at UnitedHealth Group

In related news, EVP Erin Mcsweeney sold 450 shares of the stock in a transaction that occurred on Wednesday, December 7th. The shares were sold at an average price of $542.30, for a total value of $244,035.00. Following the sale, the executive vice president now directly owns 8,736 shares in the company, valued at approximately $4,737,532.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.40% of the stock is currently owned by corporate insiders.

Institutional Trading of UnitedHealth Group

A number of hedge funds have recently modified their holdings of UNH. TimeScale Financial Inc. raised its holdings in UnitedHealth Group by 276.9% during the 3rd quarter. TimeScale Financial Inc. now owns 49 shares of the healthcare conglomerate's stock worth $25,000 after buying an additional 36 shares during the period. Pflug Koory LLC raised its holdings in UnitedHealth Group by 160.0% during the 3rd quarter. Pflug Koory LLC now owns 52 shares of the healthcare conglomerate's stock worth $26,000 after buying an additional 32 shares during the period. Urban Wealth Management LLC acquired a new stake in UnitedHealth Group during the 2nd quarter worth approximately $29,000. Knott David M Jr acquired a new stake in UnitedHealth Group during the 2nd quarter worth approximately $29,000. Finally, Belmont Capital LLC grew its stake in shares of UnitedHealth Group by 294.1% during the 3rd quarter. Belmont Capital LLC now owns 67 shares of the healthcare conglomerate's stock worth $34,000 after acquiring an additional 50 shares in the last quarter. 86.31% of the stock is currently owned by institutional investors and hedge funds.

About UnitedHealth Group

(Get Rating)

UnitedHealth Group, Inc engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience.

See Also

  • Get a free copy of the StockNews.com research report on UnitedHealth Group (UNH)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment